Combination antiretroviral
therapy (cART) suppresses human immunodeficiency virus-1 (HIV-1) replication
but is unable to permanently eradicate HIV-1. Importantly, cART does
not target HIV-1 transcription, which is reactivated in latently infected
reservoirs, leading to HIV-1 pathogenesis including non-infectious
lung, cardiovascular, kidney, and neurodegenerative diseases. To address
the limitations of cART and to prevent HIV-1-related pathogenesis,
we developed small molecules to target the noncatalytic RVxF-accommodating
site of protein phosphatase-1 (PP1) to prevent HIV-1 transcription
activation. The PP1 RVxF-accommodating site is critical for the recruitment
of regulatory and substrate proteins to PP1. Here, we confirm that
our previously developed 1E7-03 compound binds to the
PP1 RVxF-accommodating site. Iterative chemical alterations to 1E7-03 furnished a new analogue, HU-1a, with
enhanced HIV-1 inhibitory activity and improved metabolic stability
compared to 1E7-03. In a Split NanoBit competition assay, HU-1a primarily bound to the PP1 RVxF-accommodating site.
In conclusion, our study identified HU-1a as a promising
HIV-1 transcription inhibitor and showed that the PP1 RVxF-accommodating
site is a potential drug target for the development of novel HIV-1
transcription inhibitors.